Frank S Lieberman MD

Clinical Trials

• Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors Start of enrollment: 2001 Oct 09

  Completed

  Phase 2

• Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2004 Nov 01

  Completed

  Phase 2

• Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas Start of enrollment: 2006 Dec 01

  Completed

  Phase 1, Phase 2

• Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas Start of enrollment: 2009 Jan 01

  Completed

  Early Phase 1

• HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas Start of enrollment: 2009 Apr 01

  Completed

  Early Phase 1

• Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2009 Apr 15

  Completed

  Phase 3

• Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2010 Jul 01

  Completed

  Phase 2

• Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Start of enrollment: 2009 Jun 01

  Completed

  Phase 3

• Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma Start of enrollment: 2012 May 31

  Completed

  Phase 1

• Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas Start of enrollment: 2012 Oct 01

  Completed

  Early Phase 1

• Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Start of enrollment: 2013 Oct 24

  COMPLETED

  PHASE1

• Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme Start of enrollment: 2014 May 01

  Completed

  Phase 2

• Terameprocol in Treating Patients With Recurrent High Grade Glioma Start of enrollment: 2018 May 03

  Completed

  Phase 1

• Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas Start of enrollment: 2018 Oct 30

  Terminated

  Phase 1

• Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2017 Dec 15

  TERMINATED

  PHASE1

• Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM Start of enrollment: 2020 Dec 08

  ACTIVE_NOT_RECRUITING

  NA

  Roles: Contact

• Evaluation of 18F-fluciclovine (FACBC) PET/MR Uptake in Participants With Glioma Start of enrollment: 2019 Oct 22

  Completed

  Early Phase 1

  Roles: Contact

• ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) Start of enrollment: 2023 Jan 23

  RECRUITING

  PHASE3

  Roles: Principal Investigator, Contact

• Join now to see all